Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors

NCT02964247 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02964247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02964247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
March 3, 2017
Completion date
May 8, 2018
Enrollment
303 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2